Germany - First vaccine for the control of porcine Ileitis now available across Europe: Boehringer Ingelheim
Published:October 25, 2005
Source :Boehringer Ingelheim Animal Health GmbH
Boehringer Ingelheim Animal Health GmbH, have announced the pan-European launch of Enterisol® Ileitis, the first enteric vaccine to have received marketing authorization in the EU to improve pig’s weight gain and to reduce body weight variability. From now on, Enterisol® Ileitis is available in 19 European countries.
Ileitis (porcine proliferative enteropathy) is a common enteric disease of pigs which is transmitted by oral-faecal infection with the bacteria Lawsonia intracellularis. The bacteria cause severe intestinal lesions, diarrhea and gut bleedings which can negatively affect the growth performance in fattening due to reduced weight gains, extra feed costs in growing pigs and increased body weight variation at slaughter.
Ileitis is one of the most prevalent diseases worldwide which affects swine production. According to a diagnostic survey by McOrist in 2003 (1), in up to 90% of farms at least one pig was diagnosed to be infected by Lawsonia intracellularis, whereas in a most recent study (2), the prevalence is even higher (up to 100%). However, the majority of farms are infected sub-clinically i.e. without obvious symptoms, such as diarrhea or sudden deaths, as seen in the clinical form of the disease. Even these sub-clinical infections already affect farm economics negatively.
With Ileitis-affected pigs which are poorly gaining weight, the farmer faces considerable economic losses. The economic impact of clinical and sub-clinical forms of Ileitis is estimated to cost between €1.3 and €18.5 per affected pig depending on the severity and duration of the disease (3,4).
Enterisol® Ileitis is approved for the active immunization of pigs against Lawsonia intracellularis throughout the European Union. All grow/finish pigs, breeding sows and gilts are licensed to be vaccinated with Enterisol® Ileitis.
The strength of this innovative modified live vaccine is its economic impact for the farmer. In pre-approval trials in Germany investigating the economic efficiency of Enterisol® Ileitis vaccination vs. control, it has been shown that the financial benefit for the farmer can be as high as €4-5 per slaughtered pig (6).
“Enterisol® Ileitis does not only make good economic sense, it is also an essential complement to farm management tools targeting reduction of total antibiotics use in pig farms” says Dr. Hasenmaier, Head of Boehringer Ingelheim Animal Health GmbH. “This is particularly important in view of the phasing out of the few remaining antibiotic growth promoters used in the European Community by January 2006,” added Dr. Hans-Jürgen Leuchs, Member of the Board of Managing Directors, responsible for Animal Health.
In 2001, Enterisol® Ileitis has been launched in North America and is furthermore licensed in Mexico, Brazil and the Philippines.
Since 2001, approximately 100 million pigs have been vaccinated worldwide, establishing Ileitis control as an essential part of professional pig health management.
Enterisol® Ileitis is a further element in the company’s range of innovative swine vaccines (e.g. Ingelvac® PRRS MLV) and up-to-date animal health management solutions for the farmer and the veterinarian.
